The present invention relates to a process for the production and purification of Polyribosyl-ribitol Phosphate (PRP) from Haemophilus influenza type b by treatment of seed inoculum and using it for large scale high yielding production of polysaccharide from Haemophilus influenza type b. The present invention furthe...

ABSTRACT The present invention relates to the development of Pichia pastoris clones inserted with gene sequences responsible for spike protein (S- Protein subunit 1 and subunit 2) expres-sion of SARS-CoV-2 virus using recombinant DNA technology. The gene sequence was constructed artificially using available genom...

The present invention relates to the increased production of Capsular polysaccharide from a virulent Haemophilus influenza type b without the use of an external virulence enhancement agents. The increased virulence is achieved using in-vivo animal model (Balb/c mice) by growing the organism in peritoneum of the mice...

A FULLY HUMAN THERAPEUTIC MONOCLONAL ANTIBODY AGAINST SARS-COV-2 VIRUS The invention relates to a method of constructing an anti-SARS-CoV-2 specific scFv re-combinant antibody library against SARS-CoV-2 virus. The present invention relates to the processes of producing a fully human monoclonal antibody to target SA...

The invention provides fully liquid multi-antigen adjuvant based vaccine against SARS CoV-2 virus, a vaccine and a preparation method of the vaccine, relating to the technical field of vaccines. The fully liquid multi-antigen adjuvant based vaccine comprising of S1 antigen, S2 antigen, M antigen and N antigen expres...

An object of the present invention is to provide immunogenic compositions for protec-tion against S. pneumoniae, in particular against S. pneumoniae serogroup 15A. More specifically the present invention relates to the use of an immunogenic composition comprising at least one glycoconjugate from Streptococcus pneumo...

The invention provides fully liquid Bi-antigenic adjuvant based vaccine against SARS CoV-2 virus, a vaccine and a preparation method of the vaccine, relating to the technical field of vaccines. The fully liquid Bi-antigenic adjuvant based vaccine comprising of S1 and N antigen expressed in Yeast and can be deliv...

The present invention relates to Bio-pharmaceuticals. Specifically, the present invention relates to mutated Factor H binding proteins (fHbp) of N. meningitidis serogroup B. Further, the present invention relates to compositions of factor H binding protein (fHbp) for the prevention of N. meningitidis. The present in...

The present invention related to a method for the construction of Fully human ScFv naïve antibody library for the treatment of CMV infection. The present invention related to a method for the construction of fully human monoclonal antibodies for the treatment of CMV infection that targets CMV gB glycoprotein. The pr...

A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST CORONAVIRUS The present invention relates to method of constructing a specific ScFv recombinant antibody library against coronavirus. The present invention relates to the processes of producing a fully human Monoclonal Antibody to target coronavirus spike (s) glycoprotein o...

MENINGOCOCCAL HEXAVALENT COMBINATION VACCINE The present invention relates to biopharmaceuticals. The present invention relates to combination vaccine comprising hexavalent serogroup of Neisseria meningitidis for prevention and prophylaxis of infection caused by meningococcal bacteria. The present invention rela...

The present invention provides a lysin polypeptide comprising an amino acid sequence having at least 80% or at least 85% or at least 90% or at least 95% identity to a sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 16, or a fragment thereof having lysin activity. The present invention also pro...

The present invention relates to Bio-pharmaceuticals Specifically, the present invention relates to an isolated fully human monoclonal antibody or monoclonal antibody fragment or an immuno conjugate against Chikungunya. Further, the present invention relates to monoclonal antibodies against Chikungunya virus or an a...